The Oncology Institute, Inc. - Common Stock (TOI)

The Oncology Institute (TOI) reported Q2 2025 revenue of $119.8M, beating estimates, but EPS missed. Shares fell 4.6% on wider losses. Growth driven by pharmacy sales, but profitability challenges remain.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

TOI stock results show that The Oncology Institute missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family